Agios Pharmaceuticals (AGIO) Set to Announce Quarterly Earnings on Thursday

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) will be announcing its earnings results before the market opens on Thursday, October 31st. Analysts expect the company to announce earnings of $0.05 per share for the quarter. Individual interested in listening to the company's earnings conference call can do so using this link.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.60) by ($0.09). Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The firm had revenue of $8.60 million for the quarter, compared to analyst estimates of $9.34 million. During the same period in the previous year, the business posted ($1.51) EPS. Agios Pharmaceuticals's revenue for the quarter was up 28.4% on a year-over-year basis. On average, analysts expect Agios Pharmaceuticals to post $-5 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Agios Pharmaceuticals Trading Up 1.7 %

AGIO stock traded up $0.75 during mid-day trading on Thursday, hitting $45.08. The stock had a trading volume of 331,998 shares, compared to its average volume of 695,945. Agios Pharmaceuticals has a 1-year low of $19.80 and a 1-year high of $53.28. The company has a fifty day moving average of $44.64 and a 200 day moving average of $41.44. The stock has a market capitalization of $2.56 billion, a price-to-earnings ratio of -7.13 and a beta of 0.75.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, CFO Cecilia Jones sold 2,542 shares of the company's stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the transaction, the chief financial officer now directly owns 20,158 shares in the company, valued at $988,346.74. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Cecilia Jones sold 2,542 shares of the stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the sale, the chief financial officer now owns 20,158 shares in the company, valued at approximately $988,346.74. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Brian Goff sold 11,091 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $42.75, for a total value of $474,140.25. Following the sale, the chief executive officer now directly owns 78,792 shares in the company, valued at approximately $3,368,358. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.93% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Leerink Partnrs downgraded Agios Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, September 27th. StockNews.com upgraded shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday, October 16th. Scotiabank started coverage on shares of Agios Pharmaceuticals in a research report on Wednesday, October 16th. They set a "sector outperform" rating and a $51.00 target price on the stock. Cantor Fitzgerald reiterated an "overweight" rating on shares of Agios Pharmaceuticals in a research note on Friday, September 20th. Finally, Leerink Partners downgraded Agios Pharmaceuticals from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $60.00 to $56.00 in a research note on Friday, September 27th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Agios Pharmaceuticals currently has a consensus rating of "Hold" and an average target price of $52.00.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.